Tesamorelin
Also known as: TH9507
Quick summary
A stabilized analog of growth hormone–releasing hormone with a trans-3-hexenoyl group added to the N-terminus. Research focus: GHRH receptor agonism, visceral adipose tissue and IGF-1 dynamics. This page leads with SRP's low-and-slow starting dose.
Overview
A stabilized analog of growth hormone–releasing hormone with a trans-3-hexenoyl group added to the N-terminus. Clinical research has focused on how it affects visceral fat.
Looking for research material? Simple Research Peptides lists Tesamorelin (10 mg Vial) for laboratory research use.
Mechanism
A GHRH analog with a trans-3-hexenoyl group added to make it stable. It stimulates pulses of growth-hormone release and has been studied for its effects on visceral fat.
Research areas
- GHRH receptor agonism
- visceral adipose tissue
- IGF-1 dynamics
Storage & reconstitution
Typically supplied as a lyophilized powder; keep sealed vials cold (refrigerated short term, frozen for long-term holding) and away from light. Laboratories commonly reconstitute with bacteriostatic or sterile water, swirling gently rather than shaking, and keep the solution refrigerated, using it within a few weeks.
Recommended starting dose (low and slow)
| Starting dose | Fixed clinical regimen: 2 mg subcutaneous (the approved product's regimen); no step-up is described. |
|---|---|
| Frequency | Once daily; the trials ran 26 weeks. |
| Reconstitution | Example: 5 mg vial + 2 mL bacteriostatic water = 2.5 mg/mL, so 2 mg = 0.8 mL = 80 units. Refrigerate 2-8 °C, use within ~30 days. |
2 mg SC once daily, mirroring the approved product's trial regimen (26-week studies).
Studied higher doses
Studies have used doses up to the amounts below. Higher doses can be dangerous. Whether a person can reach them safely depends on height, weight, activity level, training and pre-existing conditions. We recommend following the lower starting dose above, and contacting SRP with any questions.
| Highest amount reported in studies | 2 mg per day (reference 1-2 mg). Matches the 2 mg daily dose in the 26-week phase 3 trial. |
|---|---|
| Step-up schedules reported | No step-up: the trial schedule is a fixed 2 mg once daily from day 1. give a 1-2 mg daily range. |
Route and timing
Route: Subcutaneous injection after reconstitution is the route most often described in research protocols.
Timing: Pending - to be added by SRP
Cycle length and repeat
Pending - to be added by SRP
Half-life
Approximate, for Bobby's review: Under 1 hour (roughly 25 to 40 minutes).
Side effects
Pending - to be added by SRP
Suggested bloodwork and monitoring
Draft, for Bobby's review: CBC and comprehensive metabolic panel (kidney and liver function, electrolytes) before starting and again after a few weeks; IGF-1, fasting glucose and HbA1c.
Cautions
Pending - to be added by SRP
Reconstitution calculator
Math aid only. It converts the numbers you enter; it is not dosing advice. For research use only. Prefilled with this page's vial size, reconstitution and low-and-slow starting dose where known; change any value.
Frequently asked questions
What is Tesamorelin studied for?
In research it is studied for GHRH receptor agonism, visceral adipose tissue and IGF-1 dynamics. A GHRH analog with a trans-3-hexenoyl group added to make it stable.
How is Tesamorelin given in research?
Subcutaneous injection after reconstitution is the route most often described in research protocols. See the dosing frequency block on this page for how often.
What amount should a researcher start with?
This page lists SRP's low-and-slow starting dose in the Recommended starting dose section. Higher amounts that appear in studies are listed separately with their safety context. Start with the lower dose and contact SRP with any questions.
Related peptides
Last updated: October 19, 2026